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Abstract
Innate immunity is a theme of increasing interest for HIV research. However, the term is overstretched
to cover biological barriers, cellular systems, soluble factors, signaling pathways, and effectors and is
inconsistently applied. A clearer semantic classification of the components of innate immunity is needed,
which will have direct relevance to the interpretation of human genome variation. Here, we discuss
genomic approaches that can assist in re-defining the perimeter of innate immunity. We place particular
emphasis on the characteristics of effectors of the intracellular defense against HIV and other pathogens.
Introduction
Due to their collective significance in mediating the host
response against pathogens, the genes of the interferon
response have been an area of particular focus in the field
of antiviral defense. This system includes the induction
of several hundred interferon-stimulated genes. Under-
standing the biology of interferon-stimulated genes is
challenging because of the diversity in their specificity and
breadth of action against pathogens. Among them, and of
considerable interest in the field of HIV research, are the
paradigmatic retroviral restriction factors TRIM5a,
APOBEC3G, and BST2/Tetherin [1], as well as newly
identified factors such as SAMHD1 [2,3] and SLFN11 [4].
A second challenge in studying interferon-stimulated gene
biology is understanding the apparent lack of efficacy against
HIV infection. During chronic infection, a strong inter-
feron response does not correlate with lower levels of
HIV viral load [5]. What’s more, persistent production of
interferon during chronic infection is thought to be
deleterious [5-7]. This stands in contrast with the efficacy
of exogenous administration of interferon that contributes
to active control of HIV infection in vivo [8]. Adding to the
challenge, antiviral responses can also be triggered by
interferon-independent paths [9]. Understanding the
protective and deleterious contribution of the innate
cellular response to HIV needs a more complete under-
standing of the components of such defense machinery.
In this report, we highlight approaches from genomics
that can help in these endeavors. The emphasis is on
the components of intracellular defense; thus, we do not
discuss non-cell autonomous systems that are typically
considered to be within the innate framework (e.g. NK
cells, macrophages, dendritic cells, etc.).
Genes comprising innate immunity?
There are multiple resources that list and categorize
components of innate immunity. The Gene Ontology
project (http://www.geneontology.org/) [10] includes the
term “innate immunity response” (GO:0045087); Innate-
DB (http://www.innatedb.ca) [11] identifies curated
genes, experimentally verified protein interactions, and
signaling pathways involved in innate immunity; and the
interferon-stimulated gene database [12] identifies inter-
feron-stimulated genes through expression analyses.
Additionally, recent work compiled a list of interferon-
stimulated genes that were used for extensive functional
analyses in the context of viral infection, including HIV
[13]. However, the overlap across these various lists is
limited: of 1492 genes included in one or more of the
above databases, only 25 are common to all four sets
(Figure 1). The reasons for this lack of consensus are many
fold: diversity of biology (innate immunity refers to
activities spanning many molecular and cellular func-
tions), methodological approaches for gene identification
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(e.g. microarray, functional assays), experimental setups
(e.g. different cell lines, stimuli, pathogens), and diverse
levels of confidence in annotation. More recently, a
number of initiatives have aimed at defining restricted
sub-fields, such as that of the intrinsic cellular defense [14]
and of cell-autonomous immunity [15]. Clearly, an effort
of convergence is needed as experts agree that the “function
of the several hundred genes has been comprehensively
summarized to only limited extents” [16,17]. A number
of recent papers have advanced evolutionary genomics,
human genetic approaches, and large scale functional
genomic screens that dissect components of innate
immunity.
The evolutionary view
It is well accepted that genes and cellular pathways
enriched for signals of positive selective pressure are
frequently involved in the immune response [18,19]. The
underlying concept is that evasion from, and co-evolution
with, pathogens is one of the strongest evolutionary
pressures, resulting in signals identifiable through com-
parative genomics. It is expected that genes with such
characteristics have an effector role, and that the signals
will be most pronounced at domains of direct interaction
with a pathogen [20]. Indeed, signatures of positive
selection are enriched in the various sets of innate immunity
genes (Figure 2A). The HIV restriction factors TRIM5a
APOBEC3G, BST2 and SAMHD1 are relevant examples of
genes that have undergone positive selection [20].
Gene expansion (Figure 2B) and, in particular in primates,
segmental duplications [21,22] are prominent features of
innate immunity genes. The resulting gene duplications
may lead to increased gene dosage, and neo- or sub-
functionalization [23]. The current state of functional
annotation suggests that characterization of duplicated
innate immunity genes is largely incomplete. For example,
83% of the 927 genes in InnateDB have paralogs (genes
emerging from duplication events). However, most of
these paralogs have not themselves been annotated as part
of innate immunity, despite many of them showing high
levels of sequence similarity. Therefore, estimates of
positive selection and patterns of duplication can help
establish categories within innate immunity genes. As
a corollary, these metrics could serve to annotate genes
that have not been previously considered part of innate
immunity.
A human genetics view
Exome and whole-genome sequencing in thousands of
individuals have revealed large numbers of variants that
change amino acid sequences [24]. Increasing numbers
of non-synonymous variants are a feature of genes under
positive selection, and of genes of innate immunity
Figure 1. Overlap of four innate immunity gene sets
Venn diagram representing four sets of innate immunity human genes: i) In purple, 649 genes associated to GO term “innate immune response”
(GO:0045087); ii) in green, 927 manually annotated genes from InnateDB; iii) In blue, 369 interferon-stimulated genes in the interferon-stimulated gene
database; iv) in yellow, 424 interferon-stimulated genes genes compiled by Schoggins et al. [13].
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(Figure 3). In some instances, variants code for nonsense
mutations that, when homozygous, may result in natural
knock-outs. We estimate, on the basis of 1092 exome
sequences from the 1000 Genomes Project [25], that
around 10% of innate immunity genes carry a homo-
zygous stop codon or frameshift variant that may lead to
a loss of function. As a correlate to the discussion on gene
expansion in the evolution of genomes, there is also
Figure 2. Evolutionary pattern of innate immunity gene sets
Panel (a) In grey, the genome-wide distribution (density) of dN/dS values – a measure of positive selection [34] - for 19252 protein coding genes in primates.
Lines depict the distribution of dN/dS values for genes associated with the various innate immunity sets discussed in Fig 1. Panel (b) Distribution of duplication
events occurring during the evolutionary history of a gene across the various innate immunity gene sets. The histogram depicts the proportion of genes that
have none, one or more duplications in the human genome. Dotted lines represent the duplication events for genes associated with the innate immunity gene sets.
The values of those measurements for the prototypical innate immunity genes SAMHD1, BST2, TRIM5 and APOBEC3G are indicated.
Figure 3. Burden of human genetic variation in innate immunity genes
(a) Non-synonymous coding variants in 14213 human genes in the 1000 Genome Project are plotted according to estimates of positive selection in
primates. The x-axis distributes genes from the most conserved (lower decile intervals) to the genes under positive selection (higher decile intervals).
In red, innate immunity genes (n=1143): the greater the signal of positive selection, the more frequent the identification of non-synonymous variants.
In grey, the rest of human genes. (b) This trend is not observed for synonymous variants. Horizontal black lines represent median values for the
protein coding genome.
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interest in the presence of copy number variation and, in
particular, deletions – also enriched in human genes
involved in innate immunity and the inflammatory
response [26]. The interpretation of these data includes
the possibility that greater genetic diversity provides a
benefit to the species, i.e. through balancing selection.
However, the high frequency of functional variation in
innate immune genes could also represent the substrate
of human susceptibility to infection – including the
possibility of selective immunodeficiency [27]. Exome
and whole-genome sequencing to understand rare human
variation in the setting of HIV is an important research
avenue that will complement the various genome-wide
association studies that have been published in the field
[28,29].
A functional view
There is significant room for characterization of innate
immune genes through the iterative combination of
genomic and functional assays. Some commonly applied
tools include silencing RNA and gain-of-function screens,
large-scale co-immunoprecipitation of interacting host
and pathogen proteins in cell lines, and phosphopro-
teome studies [30,31]. However, it is broadly acknowl-
edged that the interferon response is deficient in many
laboratory cell lines – which explains their utility in
pathogen research. This observation notwithstanding, the
underlying integrity of the cellular innate immune system
is rarely considered. For example, RNA sequencing of
SupT1 or 293T cells, highly permissive cell lines used in
HIV research, shows that they are poorly equipped to
respond to the incoming virus [32]. Between 25 and 50%
of innate immunity genes are downregulated or not
expressed in these cell lines, which stands in contrast with
their level of expression in primary CD4+ T cells. Thus,
analysis of expression in multiple cellular systems
generates a checkerboard of innate immunity genes that
are absent in one or more susceptible cell types, but
present in cell lines or primary cells that do not support
pathogen replication. This fact can be leveraged to further
define the perimeter of innate cellular defense. Thus,
genes of innate immunity that are missing in susceptible
cell lines, and present in primary cells, can be considered
as candidates for further investigation.
Conclusions
From a genomic perspective, a number of approaches are
useful to characterize innate immunity and thus important
to characterize the first barrier of defense against
HIV. Positive selection, gene duplication, human genetic
diversity, and differential expression across cell lines and
primary cells are quantifiable features that point to a dif-
ferential genomic landscape of effector genes participating
in protection against HIV and other pathogens [33].
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